ReviewCurrent atherosclerosis reports2006
Adiposopathy is a more rational treatment target for metabolic disease than obesity alone.
Review in Current atherosclerosis reports, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00755677 (Exploring the Health Benefits Associated With Daily Pulse Consumption in Individuals With Peripheral Arterial Disease), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploring the Health Benefits Associated With Daily Pulse Consumption in Individuals With Peripheral Arterial Disease
Who cites it
18 citing papers in PubMed, 51 citations in OpenAlex.
- Adipocyte size, adipose tissue calories, and circulating adipokines, before and after diet-induced weight loss in humans.Endocrine · 2024Trial
- Trial
- Trial
- TangNaiKang, herbal formulation, alleviates obesity in diabetic SHR/cp rats through modulation of gut microbiota and related metabolic functions.Pharmaceutical biology · 2022Article
- Interconnection between Cardiac Cachexia and Heart Failure-Protective Role of Cardiac Obesity.Cells · 2022Review
- Effect of Moderate-Intensity Aerobic Exercise on Hepatic Fat Content and Visceral Lipids in Hepatic Patients with Diabesity: A Single-Blinded Randomised Controlled Trial.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Why primary obesity is a disease?Journal of translational medicine · 2019Review
- Cardiac Obesity and Cardiac Cachexia: Is There a Pathophysiological Link?Journal of obesity · 2019Review
- Chinese Medicine in the Battle Against Obesity and Metabolic Diseases.Frontiers in physiology · 2018Review
- Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation.Journal of gastroenterology and hepatology · 2014Article
- Bariatric endocrinology: principles of medical practice.International journal of endocrinology · 2014Review
- Microarray evidences the role of pathologic adipose tissue in insulin resistance and their clinical implications.Journal of obesity · 2011Article
- Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease?International journal of clinical practice · 2009Review
- Is adiposopathy (sick fat) an endocrine disease?International journal of clinical practice · 2008Review
- Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk.Current treatment options in cardiovascular medicine · 2007Article
- Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study.Nutrition & metabolism · 2007Article
- The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys.International journal of clinical practice · 2007Article
- Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors.Vascular health and risk management · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current guidelines recommend that weight-loss therapy should be primarily based upon specific body mass index (BMI) cut-off limits. However, in the adipocentric paradigm, it is acknowledged that co-morbidities, such as type 2 diabetes mellitus, hypertension, and dyslipidemia, occur at all levels of BMI. Excessive fat mass (adiposity) in genetically susceptible individuals results in fat dysfunction (adiposopathy), which then contributes to metabolic disorders that increase the risk of atherosclerotic cardiovascular disease. In this paradigm, the term "anti-obesity" treatment might best be replaced by "anti-adiposopathy" treatment, wherein the focus is not based solely on BMI, but instead directed towards physiologically improving fat cell function and clinically improving the metabolic health of patients. This may occur through appropriate diet, physical exercise, and other lifestyle changes, and/or from drug therapies. Cannabinoid receptor antagonists and peroxisome proliferator activated receptor agonists are examples of agents that physiologically improve fat function and clinically improve metabolic disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.